데이터가 없습니다.

1. Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02 [ CLINICAL ONCOLOGY ] - 2023.02.01
2. Clinical outcomes of curative surgical resection of peritoneal metastasis in patients with colorectal cancer: A long-term follow-up study [ Cancer Medicine ] - 2023.02.01
3. A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer [ INVESTIGATIONAL NEW DRUGS ] - 2021.10.01
4. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma [ NATURE ] - 2021.06.01
5. Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines [ SCIENTIFIC REPORTS ] - 2021.03.29
6. Patterns of recurrence in patients with curative resected rectal cancer according to different chemoradiotherapy strategies: Does preoperative chemoradiotherapy lower the risk of peritoneal recurrence? [ Oncology Letters ] - 2020.11.01
7. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study [ TARGETED ONCOLOGY ] - 2019.12.01
8. Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. [ JOURNAL OF CLINICAL ONCOLOGY ] - 2019.11.20
9. 3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. [ EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ] - 2019.07.01
10. HER2Amplification and Cetuximab Efficacy inPatients With Metastatic Colorectal CancerHarboring Wild-typeRASandBRAF [ Clinical Colorectal Cancer ] - 2017.09.01
11. Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases [ AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS ] - 2016.12.01
12. Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer. [ INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS ] - 2016.10.01
13. Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models [ PLoS One ] - 2014.10.28
14. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. [ LANCET ONCOLOGY ] - 2014.10.01
15. Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. [ INVESTIGATIONAL NEW DRUGS ] - 2014.06.02
16. A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer: A Preospective, Multicenter Trial of the Korean Cancer Study Group [ AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS ] - 2014.02.01
17. Randomized phsae II study of capecitabine with or without oxaliplatin as first-line treatment for elderly of fragile patients with metastatic colorectal cancer: A prospective, multicenter trial of the Korean cancer study group CO06-01 [ AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS ] - 2013.12.01
18. 3’-Deoxy-3’- [18F] fluorothymidine positron emission tomography for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic [ JOURNAL OF NUCLEAR MEDICINE ] - 2013.08.01
19. A Phase I Study of DHP107, an Mucoadhesive Lipid Form of Oral Paclitaxel, Patients with Advanced Solid Tumors: Crossover comparisons with intravenous paclitaxel [ INVESTIGATIONAL NEW DRUGS ] - 2013.06.01
20. Second-line Cetuximab/Irinotecan Versus Oxaliplatin/Fluoropyrimidines for Metastatic Colorectal Cancer with Wild-type KRAS [ CANCER SCIENCE ] - 2013.04.01
21. Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy [ INVESTIGATIONAL NEW DRUGS ] - 2013.02.01
22. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomized, non-inferiority phase 3 trial [ LANCET ONCOLOGY ] - 2012.11.01
23. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1 [ INTERNATIONAL JOURNAL OF ONCOLOGY ] - 2012.07.01
24. Preoperative Chemoradiation With Cetuximab, Irinotecan, and Capecitabine in Patients With Locally Advanced Resectable Rectal Cancer: A Multicenter Phase II Study [ INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS ] - 2011.11.01
25. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: Long-term results of a phase II study. [ INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS ] - 2011.03.15
26. Phase I study of preoperative chemoradiation with s-1 and oxaliplatin in patients with locally advanced resectable rectal cancer. [ INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS ] - 2011.03.01
27. Curative chemoradiotherapy for isolated retroperitoneal lymph node recurrence of colorectal cancer. [ RADIOTHERAPY AND ONCOLOGY ] - 2010.11.01
28. Chemotherapy for Colorectal Cancer. [ JOURNAL OF THE KOREAN MEDICAL ASSOCIATION ] - 2010.07.01

1. 진행성 또는 전이성 직결장암이 있는 임상시험대상자에서 아미반타맙 단독요법 및 표준 화학요법과의 병용요법에 대한 제1b_2상, 라벨 공개 임상시험 - 2022.08.01 ~ 2026.10.30
2. 전이성 직장결장암 시험대상자에서 AB928 기반 병용요법의 유효성 및 안전성을 평가하는 제1b 2상, 공개, 무작위 배정 플랫폼 임상시험 - 2021.03.03 ~ 2024.01.31
3. 전이성 결장직장암 환자를 대상으로 여러 가지 면역요법 기반 치료 병용의 유효성 및 안전성을 평가하는 제1b/2상, 공개, 다기관, 무작위배정 포괄 임상시험(MORPHEUS-CRC) - 2018.08.13 ~ 2020.06.01
4. 국소 진행성 직장암 환자에서 MGMT Promoter 메틸화를 기준으로 capecitabine 기반 수술 전 선행 화학방사선요법에 temozolomide를 추가하여 효능을 비교하는 전향적 예측 인자 층화 무작위 배정 제 2상 임상 시험 - 2017.03.04 ~ 2021.02.28
5. BRAF V600E 변이 전이성 결장직장암 환자에서 안전성 도입기 동안 Encorafenib + Binimetinib + 세툭시맙을 평가하고 이리노테칸/세툭시맙 또는 FOLFIRI(주입 투여 5-플루오로우라실/폴린산/이리노테칸)/세툭시맙과 Encorafenib + 세툭시맙 ± Binimetinib을 비교하는 다기관 - 2016.11.03 ~ 2020.09.01
6. RAS 야생형 전이성 대장암 환자에서 새로운 치료 표적으로서의 HER2 유전자 과발현-증폭에 대한 연구 - 2016.01.01 ~ 2016.06.30
7. RAS 야생형 전이성 대장암 환자에서 새로운 치료 표적으로서의 HER2 유전자 과발현-증폭에 대한 연구 - 2015.07.01 ~ 2015.12.31
8. 1차 화학요법에 실패한 대장암의 간전이 환자를 대상으로 TheraSphere를 평가하기 위한 제3상 임상시험 - 2015.04.20 ~ 2019.01.31
9. 표준요법 치료에 불응하는 전이성 결장직장암 환자를 대상으로 최적의 보조 치료(BSC)와 병용한 nintedanib 을 BSC 와 병용한 위약과 비교하여 평가하기 위한 이중맹검, 무작위배정, 위약대조, 제 III 상 임상시험 - 2014.09.15 ~ 2016.07.05
10. 이전의 표준 요법에 진행한 전이성 대장암 환자의 치료로 레고라페닙 요법을 시행할 때 치료 반응 조기 예측을 위한 [18F]FLT-PET (플루오로티미딘 양전자 단층 촬영)의 유용성 연구 - 2014.04.07 ~ 2016.04.30
11. 이전의 표준 요법에 진행한 전이성 대장암 환자의 치료로 레고라페닙 요법을 시행할 때 치료 반응 조기 예측을 위한 [18F]FLT-PET (플루오로티미딘 양전자 단층 촬영)의 유용성 연구 - 2014.04.07 ~ 2016.04.30
12. 이전의 표준 요법에 진행한 전이성 대장암 환자의 치료로 레고라페닙 요법을 시행할 때 치료 반응 조기 예측을 위한 [18F]FLT-PET(플루오로티미딘 양전자 단층 촬영)의 유용성 연구 - 2014.01.01 ~ 2014.12.31
13. 소화기계 종양 환자에서 항암화학요법의 독성과 효과 예측을 위한 약물 유전체 연구 - 2013.08.09 ~ 2021.07.31
14. KRAS mutant 을 가진 대장암 환자의 새로운 치료 기술 개발 - 2010.12.01 ~ 2021.12.31

데이터가 없습니다.

      데이터가 없습니다.

 공지